- Home
- ODD vs KYMR Comparison
ODD vs KYMR Comparison
Compare ODD & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- KYMR
- Stock Information
- Founded
- ODD 2018
- KYMR 2015
- Country
- ODD Israel
- KYMR United States
- Employees
- ODD N/A
- KYMR N/A
- Industry
- ODD
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- ODD
- KYMR Health Care
- Exchange
- ODD Nasdaq
- KYMR Nasdaq
- Market Cap
- ODD 3.8B
- KYMR 3.1B
- IPO Year
- ODD 2023
- KYMR 2020
- Fundamental
- Price
- ODD $67.89
- KYMR $45.79
- Analyst Decision
- ODD Buy
- KYMR Strong Buy
- Analyst Count
- ODD 9
- KYMR 16
- Target Price
- ODD $67.89
- KYMR $58.94
- AVG Volume (30 Days)
- ODD 923.1K
- KYMR 772.9K
- Earning Date
- ODD 08-06-2025
- KYMR 08-06-2025
- Dividend Yield
- ODD N/A
- KYMR N/A
- EPS Growth
- ODD 45.36
- KYMR N/A
- EPS
- ODD 1.74
- KYMR N/A
- Revenue
- ODD $703,488,000.00
- KYMR $58,885,000.00
- Revenue This Year
- ODD $24.46
- KYMR $58.26
- Revenue Next Year
- ODD $20.26
- KYMR N/A
- P/E Ratio
- ODD $39.09
- KYMR N/A
- Revenue Growth
- ODD 26.83
- KYMR N/A
- 52 Week Low
- ODD $32.71
- KYMR $19.45
- 52 Week High
- ODD $79.18
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- ODD 40.13
- KYMR 56.87
- Support Level
- ODD $67.66
- KYMR $44.11
- Resistance Level
- ODD $70.35
- KYMR $46.88
- Average True Range (ATR)
- ODD 3.15
- KYMR 1.60
- MACD
- ODD -0.74
- KYMR -0.18
- Stochastic Oscillator
- ODD 2.82
- KYMR 65.91
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.